Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Ultravate: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Ultravate - General Information

Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

 

Pharmacology of Ultravate

Not Available

 

Ultravate for patients

Patients using topical corticosteroids should receive the following information and instructions:

1. The medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

2. The medication should not be used for any disorder other than that for which it was prescribed.

3. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.

4. Patients should report to their physician any signs of local adverse reactions.

5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressing.

 

Ultravate Interactions

No information provided.

 

Ultravate Contraindications

ULTRAVATE (halobetasol propionate cream) Cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

 

Additional information about Ultravate

Ultravate Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Mechanism Of Action
Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Generic Name
Halobetasol Propionate
Drug Category
Anti-inflammatory Agents; Vasoconstrictor Agents
Drug Type
Small Molecule; Approved
Other Brand Names containing Halobetasol Propionate
Halobetasol; Ulobetasol Propionate; Ultravate;
Absorption
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Dosage Forms of Ultravate
Ointment Topical
Chemical IUPAC Name
[(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
Chemical Formula
C25H31ClF2O5
Organisms Affected
Humans and other mammals